A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours

Neuroendocrine Tumors Clinical Trial

Official title:

A Phase II Study to Assess the Activity and Safety of TH-302 in Combination With Sunitinib in Treatment-naïve Patients With Well- and Moderately-differentiated Metastatic Pancreatic Neuroendocrine Tumours (pNET)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02402062
• Other study ID #: GETNE-1408
• Secondary ID: 2014-004072-30
• Status: Completed
• Phase: Phase 2
• Start date: May 11, 2015
• Est. completion date: January 10, 2020

Study information

• Verified date: July 2020
• Source: Grupo Espanol de Tumores Neuroendocrinos
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety and the efficacy of the combination of the drugs TH-302 and sunitinib in metastatic neuroendocrine tumours.

Description:

The purpose of this study is to determine the safety and the efficacy of the combination of the drugs TH-302 and sunitinib in Treatment-naïve patients with well- and moderately-differentiated metastatic Pancreatic Neuroendocrine Tumours (pNET).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 17
• Est. completion date: January 10, 2020
• Est. primary completion date: May 31, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female, 18 years of age or older.

• Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

• Histologically proven diagnosis of pancreatic neuroendocrine tumors (pNET) with Ki67 assessment of = 20% (well and moderately differentiated)

• Evidence of unresectable disease or metastatic disease. Locally advanced disease must not be amendable to resection or radiation therapy with curative intent.

• Patients may be treated with somatostatin analogues prior or during the trial. Concomitant or prior interferon treatment is not permitted.

• Documented progression disease by CT scan, magnetic resonance (MR) or Octreoscan in 12 months prior basal visit.

• Measurable disease as per RECIST. Measurable lesions that have been previously radiated will not be considered target lesions unless increase in size has been observed following completion of radiation therapy.

• Patient has to be able to swallow the medication.

• Life expectancy greater than 12 weeks.

• The definitions of minimum adequacy for organ function required prior to study entry are as follows:

• Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) = 2.5 x upper limit of normal (ULN), or AST and ALT = 5 x ULN if liver function abnormalities are due to underlying malignancy

• Total serum bilirubin = 1.5 x ULN

• Serum albumin = 3.0 g/dL

• Absolute neutrophil count (ANC) = 1500/µL

• Platelets = 100,000/µL

• Hemoglobin = 5,6 mmol/L (9.0 g/dL)

• Creatinin clearance > 40 mL/min (Cockcroft and Gault formula)

• Adequate cardiac function: 12-lead ECG without pathologic findings (clinically significant alterations are allowed) and Echocardiogram / Normal multiple gated acquisition scan (MUGA) (LVEF> 50%)

• Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrollment.

• Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.

Exclusion Criteria:

• Previous treatments with chemotherapy, monoclonal antibodies anti-vascular endothelial growth factor (VEGF), tyrosine kinase inhibitors, mammalian target of rapamycin (mTOR) inhibitors, or interferon are not permitted for the advanced disease.

• Prior treatment on another hypoxia-activated prodrug under clinical trial.

• Major surgery, radiation therapy, or systemic therapy within 3 weeks of study randomization except palliative radiotherapy to non-target metastatic lesions.

• Prior high-dose chemotherapy requiring hematopoietic stem cell rescue.

• Immunosuppressive drugs such as cyclosporine, tacrolimus, azathioprine, or long-term oral glucocorticoids taken concurrently or within last 3 months prior to randomization

• Treatment with known inhibitors or inductors of cytochrome P450 3A4 (CYP3A4) or that prolong the QT interval in the previous 7 days.

• Prior radiation therapy to > 25% of the bone marrow.

• Current treatment on another clinical trial.

• Uncontrolled brain metastases, spinal cord compression, carcinomatous meningitis, or leptomeningeal disease. Patients should have completed surgery or radiation therapy for existing brain metastases, should not have documented increase in size over the previous 3 months prior to first dose of treatment on study and should be asymptomatic.

• Diagnosis of any second malignancy within the last 3 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix.

• Any of the following within the 12 months prior to starting study treatment:

• myocardial infarction,

• severe/unstable angina,

• coronary/peripheral artery bypass graft,

• congestive heart failure class III or IV of the New York Heart Association (NYHA) or patients with clinical history of congestive heart failure class III or IV of the NYHA, unless an echocardiogram or MUGA in the previous 3 months to selection shows a LVEF ? 45 %

• significant heart valve disease

• cerebrovascular accident including transient ischemic attack

• pulmonary embolus.

• Ongoing cardiac dysrhythmias of NCI Common Toxicity Criteria for Adverse Effects (CTCAE) grade = 2, atrial fibrillation of any grade, or corrected QT interval (QTc) interval >450 msec for males or >470 msec for females.

• Hypertension that cannot be controlled by medications (>150/100 mmHg despite optimal medical therapy)

• Chronic obstructive pulmonary disease (COPD) or any other disease concurrent with hypoxemia or oxygen saturation < 90% after a march of two minutes.

• Current treatment with therapeutic doses of Coumadin (low dose Coumadin up to 2 mg PO daily for deep vein thrombosis prophylaxis is allowed).

• Known human immunodeficiency virus infection.

• Pregnancy or breastfeeding. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) prior to inclusion.

• Previous allergic reaction to components structurally similar to TH-302 or sunitinib or any of the excipients of drugs.

• Non-healing wound, fistulae, active peptic ulcer or bone fracture.

• Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.

Related Conditions & MeSH terms

• Neuroendocrine Tumors
• Pancreatic Neoplasms

Intervention

Drug:
• TH-302 + Sunitinib
Combination of the two drugs in cycles of 28 days, described as follows: Sunitinib: 37,5 mg/day Oral everyday of each 28 day cycle. TH-302: 340 mg/m2 IV on days 8, 15 and 22 of each cycle.

Locations

Country	Name	City	State
Spain	Hospital Universitari Vall d'Hebron	Barcelona
Spain	Hospital Provincial de Castellón	Castelló	Valencia
Spain	Hospital Universitario Virgen de las Nieves	Granada
Spain	Institut Catalá d'Oncologia L'Hospitalet	L'Hospitalet de Llobregat	Barcelona
Spain	Hospital Universitario 12 de Octubre	Madrid
Spain	Hospital Universitario La Paz	Madrid
Spain	Hospital Universitario Ramón y Cajal	Madrid
Spain	Hospital Universitario Virgen de la Victoria	Málaga
Spain	Hospital Universitario Marqués de Valdecilla	Santander	Cantabria
Spain	Hospital Universitario Virgen del Rocío	Sevilla

Sponsors (3)

Lead Sponsor	Collaborator
Grupo Espanol de Tumores Neuroendocrinos	Pfizer, Threshold Pharmaceuticals

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response Rate	Objective response rate: percentage of patients in whom a complete response (CR) or a partial response (PR) is confirmed according Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria in relation to the total of the analyzed population.; Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions	approximately 36 months
Secondary	Progression Free Survival (PFS)	Time between the start of study treatment to date of the first objective evidence of radiological progression or patient death due to any cause; which comes first.	approximately 36 months
Secondary	Time to Tumour Progression (TTP)	It is defined as the time between the start of study treatment to date of the first objective evidence of radiological progression.	approximately 36 months
Secondary	Duration of Response (DR)	It is defined as the time between the start from the first documentation of objective response (CR or PR) which is subsequently confirmed until the first objective evidence of radiological progression or death from any cause. DR is calculated only in the subgroup of patients with an objective response (CR + PR).	approximately 36 months
Secondary	Overall Survival (OR)	It is defined as the time between the start of study treatment to date of death from any cause. If it were impossible to obtain confirmation of the death, survival will be censored with the date of the last Visit that it is satisfied that the patient was alive.	approximately 36 months
Secondary	Safety (Adverse Events)	Safety will be assessed according to the reports of adverse events, the frequency of treatment discontinuations due to adverse events, laboratory evaluations or ECG	time between the date of signing the informed consent until 28 days after the last dose of study drug, , an average of 2 years
Secondary	Biomarkers in Serum and Tumor Tissue	Assess the predictive/prognostic value of the analysed biomarkers in plasm and tumour.	approximately 36 months